Publikationen Lehrstuhl 1

Für weitere Publikationen besuchen Sie bitte Pubmed

2018

Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Gut 2018; 67 (7):1328-1341 doi:10.1136/gutjnl-2017-315402

Arndt S, Unger P, Berneburg M, Bosserhoff AK, Karrer S
Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode.
J Dermatol Sci 2018; 89 (2):181-190 doi:10.1016/j.jdermsci.2017.11.008

Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L
Can checkpoint inhibitor therapy improve response to chemotherapy?
J Cancer Res Clin Oncol 2018; 144 (1):183-185 doi:10.1007/s00432-017-2546-8

Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C
ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis.
Gut 2018; 67 (4):746-756 doi:10.1136/gutjnl-2016-312485

Sasahira T, Bosserhoff AK, Kirita T
The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer.
Pathol Int 2018; 68 (5):278-286 doi:10.1111/pin.12672

Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic „dual-hit“ option.
Oncotarget 2018; 9 (3):3605-3618 doi:10.18632/oncotarget.23188

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK
MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma.
Pigment Cell Melanoma Res 2018; doi:10.1111/pcmr.12698

Schott M, de Jel MM, Engelmann JC, Renner P, Geissler EK, Bosserhoff AK, Kuphal S
Selenium-binding protein 1 is down-regulated in malignant melanoma.
Oncotarget 2018; 9 (12):10445-10456 doi:10.18632/oncotarget.23853

Krupar R, Hautmann MG, Pathak RR, Varier I, McLaren C, Gaag D, Hellerbrand C, Evert M, Laban S, Idel C, Sandulache V, Perner S, Bosserhoff AK, Sikora AG
Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.
Am J Pathol 2018; 188 (1):72-83 doi:10.1016/j.ajpath.2017.09.013

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Oncogene 2018; 37 (7):897-911 doi:10.1038/onc.2017.391

Dietrich P, Bosserhoff AK
Melanoma sponge on pigmentation gene to reduce tumour-suppressive microRNAs.
Pigment Cell Melanoma Res 2018; 31 (3):350-351 doi:10.1111/pcmr.12660

Mahli A, Koch A, Fresse K, Schiergens T, Thasler WE, Schönberger C, Bergheim I, Bosserhoff A, Hellerbrand C
Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis.
Lab Invest 2018; 98 (12):1614-1626 doi:10.1038/s41374-018-0112-x

2017

Christoph J, Knell C, Bosserhoff A, Naschberger E, Stürzl M, Rübner M, Seuss H, Ruh M, Prokosch HU, Sedlmayr B
Usability and Suitability of the Omics-Integrating Analysis Platform tranSMART for Translational Research and Education.
Appl Clin Inform 2017; 8 (4):1173-1183 doi:10.4338/ACI-2017-05-RA-0085

Uslu U, Schliep S, Schliep K, Erdmann M, Koch HU, Parsch H, Rosenheinrich S, Anzengruber D, Bosserhoff AK, Schuler G, Schuler-Thurner B
Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Anticancer Res. 2017;37(9): 5033-5037

Maisch T, Bosserhoff AK, Unger P, Heider J, Shimizu T, Zimmermann JL, Morfill GE, Landthaler M, Karrer S
Investigation of toxicity and mutagenicity of cold atmospheric argon plasma.
Environ Mol Mutagen. 2017;58(3): 172-177

Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C
ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis.
Gut. 2017;

Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Gut. 2017;

Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L
Can checkpoint inhibitor therapy improve response to chemotherapy?
J Clin Oncol. 2017;35 15: –

Arndt S, Unger P, Berneburg M, Bosserhoff AK, Karrer S
Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode.
J Dermatol Sci. 2017;

Linck L, Voller D, Bosserhoff A
MicroRNA-vermittelte Regulation von Argonaute2 im malignen Melanom
J Dtsch Dermatol Ges. 2017;15 3: 1-1

Stieglitz D, Lamm S, Bosserhoff A, Karrer S, Echtenacher B, Hellerbrand C, Feuerer L, Braig S, Kuphal S, Arndt S
BMP6-induced Modulation of the Tumor Microenvironment
J Dtsch Dermatol Ges. 2017;15 3: 84-84

Maurus K, Hufnagel A, Geiger F, Graf S, Berking C, Heinemann A, Paschen A, Kneitz S, Stigloher C, Geissinger E, Otto C, Bosserhoff A, Schartl M, Meierjohann S
The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Oncogene. 2017;36(36): 5110-5121

Kuphal S, Schneider N, Massoumi R, Hellerbrand C, Bosserhoff AK
UVB radiation represses CYLD expression in melanocytes
Oncol Lett. 2017;14(6): 7262-7268

Bosserhoff AK, Schneider N, Ellmann L, Heinzerling L, Kuphal S
The neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry.
Oncotarget. 2017;8(1): 1117-1131

Sommer J, Mahli A, Freese K, Schiergens TS, Kuecuekoktay FS, Teufel A, Thasler WE, Müller M, Bosserhoff AK, Hellerbrand C
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Oncotarget. 2017;8(8): 13059-13072

Meyer T, Koch A, Ebert EV, Czech B, Mueller M, Bosserhoff A, Lang SA, Hellerbrand C
Effect of melanoma cells on proliferation and migration of activated hepatic stellate cells in vitro.
Pathol Res Pract. 2017;213(4): 400-404

Dietrich P, Bosserhoff AK
Melanoma sponge on pigmentation gene to reduce tumour-suppressive microRNAs.
Pigment Cell Melanoma Res. 2017;

Krupar R, Hautmann M, Pathak R, Varier I, McLaren C, Gaag D, Hellerbrand C, Evert M, Laban S, Idel C, Sandulache V, Perner S, Bosserhoff A, Sikora A
Immuno-metabolic determinants of chemoradiotherapy response and survival in head and neck squamous cell carcinoma (SCC)
Virchows Arch. 2017;471 1: S151-S151

2016

Schummer P, Kuphal S, Vardimon L, Bosserhoff AK, Kappelmann M
Specific c-Jun target genes in malignant melanoma.
Cancer Biol Ther. 2016;17(5): 486-97

Ruedel A, Schott M, Schubert T, Bosserhoff AK
Robo3A and Robo3B expression is regulated via alternative promoters and mRNA stability.
Cancer Cell Int. 2016;16: 71

Strobl C, Henrich F, Kreutz M, Bosserhoff AK, Mackensen A, Aigner M
5 ‚-deoxy-5‘-methylthioadenosine (MTA) impairs human T -cell functions and constitutes a novel immuno-suppressing tumor metabolite
Cancer Res. 2016;76 14: –

de Jel MM, Schiffner S, Kuphal S, Bosserhoff AK
Loss of CYLD promotes melanoma progression
Exp Dermatol. 2016;25(3): E38-E38

Reinders Y, Völler D, Bosserhoff AK, Oefner PJ, Reinders J
Testing Suitability of Cell Cultures for SILAC-Experiments Using SWATH-Mass Spectrometry.
Methods Mol Biol. 2016;1394: 101-8

Sasahira T, Nishiguchi Y, Fujiwara R, Kurihara M, Kirita T, Bosserhoff AK, Kuniyasu H
Storkhead box 2 and melanoma inhibitory activity promote oral squamous cell carcinoma progression.
Oncotarget. 2016;7(18): 26751-64

Sasahira T, Kirita T, Nishiguchi Y, Kurihara M, Nakashima C, Bosserhoff AK, Kuniyasu H
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma.
Oncotarget. 2016;7(21): 31137-52

Ott CA, Linck L, Kremmer E, Meister G, Bosserhoff AK
Induction of exportin-5 expression during melanoma development supports the cellular behavior of human malignant melanoma cells.
Oncotarget. 2016;7(38): 62292-62304

Dietrich P, Bosserhoff AK
DNMT targets MiRacle torching TORCh.
Pigment Cell Melanoma Res. 2016;29(4): 399-401

Böhme I, Bosserhoff AK
Acidic tumor microenvironment in human melanoma.
Pigment Cell Melanoma Res. 2016;29(5): 508-23

Moeckel S, Vollmann-Zwerenz A, Proescholdt M, Brawanski A, Riemenschneider MJ, Bogdahn U, Bosserhoff AK, Spang R, Hau P
Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro.
PLoS ONE. 2016;11(3): e0151312

Limm K, Dettmer K, Reinders J, Oefner PJ, Bosserhoff AK
Characterization of the Methylthioadenosine Phosphorylase Polymorphism rs7023954 – Incidence and Effects on Enzymatic Function in Malignant Melanoma.
PLoS ONE. 2016;11(8): e0160348

Völler D, Linck L, Bruckmann A, Hauptmann J, Deutzmann R, Meister G, Bosserhoff AK
Argonaute Family Protein Expression in Normal Tissue and Cancer Entities.
PLoS ONE. 2016;11(8): e0161165

2015

Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C.
Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Oncotarget. 2015 Oct 206(32):32748-60. doi: 10.18632/oncotarget.4977.

Niebler S, Angele P, Kujat R, Bosserhoff AK.
Hypoxia-Inducible Factor 1 Is an Inductor of Transcription Factor Activating Protein 2 Epsilon Expression during Chondrogenic Differentiation.
Biomed Res Int. 20152015:380590. doi: 10.1155/2015/380590.

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK.
Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
Int J Clin Exp Pathol. 2015 Jun 18(6):6607-16. Retraction in: Int J Clin Exp Pathol. 20158(11):15497.

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK.
Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
Int J Clin Exp Pathol. 2015 May 18(5):4953-62.

Dietrich P, Bosserhoff AK.
Modifying microRNAs–another piece of the melanoma puzzle.
Pigment Cell Melanoma Res. 2015 Sep28(5):488-9. doi: 10.1111/pcmr.12389. No abstract available.

Niebler S, Schubert T, Hunziker EB, Bosserhoff AK.
Activating enhancer binding protein 2 epsilon (AP-2ε)-deficient mice exhibit increased matrix metalloproteinase 13 expression and progressive osteoarthritis development.
Arthritis Res Ther. 2015 May 1217:119. doi: 10.1186/s13075-015-0648-8.

Delic S, Thuy A, Schulze M, Proescholdt MA, Dietrich P, Bosserhoff AK, Riemenschneider MJ.
Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.
Genes Chromosomes Cancer. 2015 Jul54(7):433-43. doi: 10.1002/gcc.22255.

Arndt S, Landthaler M, Zimmermann JL, Unger P, Wacker E, Shimizu T, Li YF, Morfill GE, Bosserhoff AK, Karrer S.
Effects of cold atmospheric plasma (CAP) on ß-defensins, inflammatory cytokines, and apoptosis-related molecules in keratinocytes in vitro and in vivo.
PLoS One. 2015 Mar 1310(3):e0120041. doi: 10.1371/journal.pone.0120041.

2014

Yeremenko N, Härle P, Cantaert T, van Tok M, van Duivenvoorde LM, Bosserhoff A, Baeten D: The cartilage protein Melanoma Inhibitory Activity contributes to inflammatory arthritis. Rheumatology (Oxford) 53 (3): 438-447 (2014) IF 4.2

Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R: CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 35 (2): 461-468 (2014) IF 5.6

Maerker DA, Zeschnigk M, Nelles J, Lohmann DR, Worm K, Bosserhoff AK, Krupar R, Jägle H: BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol 98:224-227 (2014) IF 2.7

Ruedel A, Stark K, Kaufmann S, Bauer R, Reinders J, Rovensky J, Blažičková S, Oefner PJ, Bosserhoff AK: N-cadherin promoter polymorphisms and risk of osteoarthritis. FASEB J 28 (2): 683-691 (2014) IF 5.7

Schmid R, Bosserhoff AK: Redundancy in regulation of chondrogenesis in MIA/CD-RAP-deficient mice. Mech Dev 131: 24-34 (2014) IF 2.4

Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM, Kuphal S: Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes for apoptosis in melanoma. Mol Carcinog 53 (8): 635-647 (2014) IF 3.2

Dorn C, Engelmann J, Saugspier M, Koch A, Hartmann A, Müller M, Spang R, Bosserhoff A, Hellerbrand C: Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest 94 (4): 394-408 (2014) IF 4.0

Graf SA, Busch C, Bosserhoff AK, Besch R, Berking C: SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity (MIA). J Invest Dermatol 134 (8): 2212-2220 (2014) IF 6.4

de Jel MM, Engelmann JC, Kunz M, Schiffner S, Kuphal S, Bosserhoff AK: Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations. Pigment Cell Melanoma Res 27 (4): 678-680 (2014) IF 5.8

Bosserhoff AK, Hofmeister S, Ruedel A, Schubert T: DCC is expressed in a CD166-positive subpopulation of chondrocytes in human osteoarthritic cartilage and modulates CRE activity. Int J Clin Exp Pathol 7 (5): 1947-1956 (2014) IF 2.2

Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss T, Oefner P, Müller M, Bosserhoff AK, Hellerbrand C: Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis 35 (6): 1407-1415 (2014) IF 5.6

Sasahira T, Kirita T, Yamamoto K, Ueda N, Kurihara M, Matsushima S, Bhawal UK, Bosserhoff AK, Kuniyasu H: Transport and Golgi organisation protein 1 is a novel tumour progressive factor in oral squamous cell carcinoma. Eur J Cancer 50 (12): 2142-2151 (2014) IF 4.8

Voeller D, Bosserhoff AK: Reply to comment on: Strong reduction of AGO2 expression in melanoma and cellular consequences. Br J Cancer 111 (8): 1673 (2014) IF 5.1

Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, Hartmann A, Bosserhoff AK, Hellerbrand C: Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut 0:1–9. doi:10.1136/gutjnl-2014-306968 (2014) (* both last authors contributed equally) IF 13.3

Krupar R, Robold K, Gaag D, Spanier G, Kreutz M, Renner K, Hellerbrand C, Hofstaedter F, Bosserhoff AK: Immunologic and metabolic characteristics of HPV-negative and HPV-positive oropharyngeal squamous cell carcinomas. Virchows Arch 465 (3): 299-312 (2014) IF 2.6

Schiffner S, Braunger BM, de Jel MM, Coupland SE, Tamm ER, Bosserhoff AK: Tg(Grm1) transgenic mice: a murine model that mimics spontaneous uveal melanoma in humans? Exp Eye Res 127: 59-68 (2014) IF 3.0

Limm K, Wallner S, Milenkovic VM, Wetzel CH, Bosserhoff AK: The metabolite 5’-methylthioadenosine (MTA) signals through the adenosine receptor A2B in melanoma. Eur J Cancer 50 (15): 2714-2724 (2014) IF 4.8

Moeckel S, Meyer K, Leukel P, Heudorfer F, Seliger C, Stangl C, Bogdahn U, Proescholdt M, Brawanski A, Vollmann-Zwerenz A, Riemenschneider MJ, Bosserhoff AK, Spang R, Hau P: Response-predictive gene expression profiling of glioma progenitor cells in vitro. PlosOne 9 (9): e108632 (2014) IF 3.7

Books:

Bosserhoff AK (Editor): “Melanoma Development – Molecular Biology, Genetics and Clinical Application”. Springer (2011) dx.doi.org/10.1007/978-3-7091-0371-5

Bosserhoff AK (Guest Editor): Special issue on “Melanoma Research”, Eur J Cell Biol 93 (1-2): 1-86 (2014)